Granted Patent
B2
US 12,281,335 · App. 18/518,000 · Granted Apr 22, 2025
Methods and compositions for delivery of viral vectors across the blood-brain barrier
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein is an adeno-associated virus (AAV) particle comprising a surface-bound peptide that enhances transduction of cells across the blood-brain barrier (BBB). Also disclosed herein is a modified AAV capsid protein comprising an insertion of a polypeptide that enhances transduction of cells across the BBB, and an AAV particle comprising the modified AAV capsid protein. Specific peptides are provided. Pharmaceutical formulations and method of administering/delivering a nucleic acid to a cell of the brain and/or central nervous system are also disclosed.
Claims (15)
1. An adeno-associated virus (AAV) particle comprising a surface-bound peptide, wherein the peptide bound to the surface of the AAV particle is selected from the group consisting of:
a) PB5-3 (SEQ ID NO:133);
b) PB5-5 (SEQ ID NO: 134);
c) PB5-14 (SEQ ID NO:135); and
d) any combination of (a)-(c) above.
2. The AAV particle of claim 1 , wherein the AAV is of a serotype or any combination of serotypes selected from the group consisting of AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, Avian AAV, Avian AAV strain DA-1, Bovine AAV, AAV11, AAV12, Clade A, Hu.48, Hu 43, Hu 44, Hu 46, Clade B, Hu. 19, Hu. 20, Hu 23, Hu22, Hu24, Hu21, Hu27, Hu28, Hu 29, Hu63, Hu64, Hu13, Hu56, Hu57, Hu49, Hu58, Hu34, Hu35, Hu45, Hu47, Hu51, Hu52, Hu T41, Hu S17, Hu T88, Hu T71, Hu T70, Hu T40, Hu T32, Hu T17, Hu LG15, Clade C, Hu9, Hu10, Hu11, Hu53, Hu55, Hu54, Hu7, Hu18, Hu15, Hu16, Hu25, Hu60, Ch5, Hu3, Hu1, Hu4, Hu2, Hu61, Clade D, Rh62, Rh48, Rh54, Rh55, Cy2, Rh35, Rh37, Rh36, Cy6, Cy4, Cy3, Cy5, Rh13, Clade E, Rh38, Hu66, Hu42, Hu67, Hu40, Hu41, Hu37, Rh40, Rh2, Bb1, Bb2, Rh10, Hu17, Hu6, Rh25, Pi2, Pi1, Pi3, Rh57, Rh50, Rh49, Hu39, Rh58, Rh61, Rh52, Rh53, Rh51, Rh64, Rh43, AAV8, Rh8, Rh1, Clade F, Hu14, Hu31, Hu32, Rh34, Rh33, and Rh32.
3. The AAV particle of claim 1 , wherein the AAV is AAV8, AAV9, AAV2, AAV2i8, AAV9.45 or any variant, mutant, or combination thereof.
4. The AAV particle of claim 1 , wherein the peptide bound to the surface of the AAV particle is present on the AAV particle surface in an amount ranging from about 2000 protein molecules per AAV particle to about 4×10 7 protein molecules per AAV particle.
5. The AAV particle of claim 1 , comprising a heterologous nucleic acid molecule.
6. The AAV particle of claim 1 , wherein said AAV particle comprising the surface-bound peptide has enhanced transduction activity across the blood brain barrier (BBB) relative to an AAV particle lacking the surface-bound peptide.
7. The AAV particle of claim 1 , wherein said AAV particle comprising the surface-bound peptides has enhanced transduction activity of cells of the brain and/or central nervous system.
8. The AAV particle of claim 1 that is comprised within a pharmaceutically acceptable carrier.
9. A method of administering a nucleic acid to a cell of the brain and/or central nervous system, comprising contacting the cell with the AAV particle of claim 1 .
10. The method of claim 9 , wherein the AAV particle is administered systemically.
11. The method of claim 10 , wherein the subject is a human subject.
Continuity (3)
Division
16956306
Provisional Application
62607662
· Dec 19, 2017
References Cited (121)
US 20060127358A1
· Muzyczka et al.
· 2006
[cited by applicant]
US 20170253643A1
· Yamashita et al.
· 2017
[cited by applicant]
WO 2004099423A1
· 2004
[cited by applicant]
WO 2013123503A1
· 2013
[cited by applicant]
WO 2013158879A1
· 2013
[cited by applicant]
WO 2016035820A1
· 2016
[cited by applicant]
WO 2016054554A1
· 2016
[cited by applicant]
WO 2017136536A1
· 2017
[cited by applicant]
WO 2017176651A1
· 2017
[cited by applicant]
Zhang et al. “Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain” Biomaterials 281:121340. (Year: 2022).
[cited by examiner]
Frieden , et al., “A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions”, PNAS, 114(24):6292-6297 (2017).
[cited by applicant]
Arbetman et al. “Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties” Journal of Virology, 79(24):15238-15245 (2005).
[cited by applicant]
Asokan et al. “Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle” Nature Biotechnology, 28(1):79-82 (2010).
[cited by applicant]
Asuri et al. “Directed Evolution of Adeno-associated Virus for Enhanced Gene Delivery and Gene Targeting in Human Pluripotent Stem Cells” Molecular Therapy, 20(2):329-338 (2012).
[cited by applicant]
Banks, William A. “Characteristics of compounds that cross the blood-brain barrier” BMC Neurology, 9(Suppl 1):S3 (2009).
[cited by applicant]
Bello et al. “Novel Adeno-associated Viruses Derived From Pig Tissues Transduce Most Major Organs in Mice” Scientific Reports, 4:6644 (pp. 1-11) (2014).
[cited by applicant]
Bennett et al. “AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness” Gene Therapy, 4 (120ra115) (pp. 1-10) (2012).
[cited by applicant]
Bossis et al. “Cloning of an Avian Adeno-Associated Virus (AAAV) and Generation of Recombinant AAAV Particles” Journal of Virology, 77(12):6799-6810 (2003).
[cited by applicant]
Bowles et al. “Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector” Molecular Therapy, 20(2):443-455 (2012).
[cited by applicant]
Carlon et al. “Efficient Gene Transfer Into the Mouse Lung by Fetal Intratracheal Injection of rAAV2/6.2” Molecular Therapy, 18(12):2130-2138 (2010).
[cited by applicant]
Cearley et al. “Transduction Characteristics of Adeno-associated Virus Vectors Expressing Cap Serotypes 7, 8, 9, and Rh10 in the Mouse Brain” 13(3):528-537 (2006).
[cited by applicant]
Chai et al. “Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion” Journal of Controlled Release, 262:348-356 (2017).
[cited by applicant]
Choudhury et al. “Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector” Molecular Therapy, 24(4):726-735 (2016).
[cited by applicant]
Cronin et al. “Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno- associated virus capsid and promoter” EMBO Molecular Medicine, 6(9):1175-1190 (2014).
[cited by applicant]
Dalkara et al. “In Vivo-Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous” Science Translational Medicine, 5(189):189ra76 (2013).
[cited by applicant]
Davidoff et al. “Comparison of the Ability of Adeno-associated Viral Vectors Pseudotyped with Serotype 2, 5, and 8 Capsid Proteins to Mediate Efficient Transduction of the Liver in Murine and Nonhuman Primate Models” Mo…
[cited by applicant]
Daya et al. “Gene Therapy Using Adeno-Associated Virus Vectors” Clinical Microbiology Reviews, 21(4):583-593 (2008).
[cited by applicant]
Demeule et al. “Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2” Journal of Neurochemistry, 106:1534-1544 (2008).
[cited by applicant]
Deverman et al. “Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain” Nature Biotechnology, 34(2):204-209 (2016).
[cited by applicant]
Dismuke et al. “Biosafety of recombinant adeno-associated virus vectors” Current Gene Therapy, 13(6):434-452 (2013) (Abstract only).
[cited by applicant]
Dufes et al. “Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells” Therapeutic Delivery, 4:629-640 (2013).
[cited by applicant]
Erazo-Oliveras et al. “Improving the Endosomal Escape of Cell-Penetrating Peptides and Their Cargos: Strategies and Challenges” Pharmaceuticals, 5:1177-1209 (2012).
[cited by applicant]
Excoffon et al. “Directed evolution of adeno-associated virus to an infectious respiratory virus” Proceedings of the National Academy of Sciences USA, 106(10):3865-3870 (2009).
[cited by applicant]
Extended European Search Report corresponding to European Patent Application No. 18890295.1 (12 pages) (dated Sep. 2, 2021).
[cited by applicant]
Fosgerau et al. “Peptide therapeutics: current status and future directions” Drug Discovery Today, 20(1):122-128 (2015).
[cited by applicant]
Foust et al. “Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes” Nature Biotechnology, 27(1):59-65 (2009).
[cited by applicant]
Gabriel et al. “Bioengineering of AAV2 Capsid at Specific Serine, Threonine, or Lysine Residues Improves Its Transduction Efficiency in Vitro and in Vivo” Human Gene Therapy Methods, 24(2):80-93 (2013).
[cited by applicant]
Gaillard et al. “Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation” Journal of Controlled Release, 164:364-369 (2012) (Abstract only).
[cited by applicant]
Gao et al. “Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues” Journal of Virology, 78 (12):6381-6388 (2004).
[cited by applicant]
Geoghegan et al. “Chondroitin Sulfate is the Primary Receptor for a Peptide-Modified AAV That Targets Brain Vascular Endothelium In Vivo” Molecular Therapy—Nucleic Acids, 3(e202) (pp. 1-13) (2014).
[cited by applicant]
Girod et al. “Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2” Nature Medicine, 5(9):1052-1056 (1999).
[cited by applicant]
Gray et al. “Directed Evolution of a Novel Adeno-associated Virus (AAV) Vector That Crosses the Seizure-compromised Blood-Brain Barrier (BBB)” Molecular Therapy, 18(3):570-578 (2010).
[cited by applicant]
Grifman et al. “Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus Capsids” Molecular Therapy, 3(6):964-975 (2001).
[cited by applicant]
Grimm et al. “In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses” Journal of Virology, 82(12):5887-5911 (2008).
[cited by applicant]
Hastie et al. “Adeno-Associated Virus at 50: A Golden Anniversary of Discovery, Research, and Gene Therapy Success—A Personal Perspective” Human Gene Therapy, 26(5):257-265 (2015).
[cited by applicant]
He et al. “Kinetics of Adeno-Associated Virus Serotype 2 (AAV2) and AAV8 Capsid Antigen Presentation In Vivo Are Identical” Human Gene Therapy, 24(5):545-553 (2013).
[cited by applicant]
Hordeaux et al. “The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice” Molecular Therapy, 26 (3):664-666 (2018).
[cited by applicant]
Huang et al. “Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector” Molecular Therapy, 24(6):1062-1069 (2016).
[cited by applicant]
Iida et al. “Systemic Delivery of Tyrosine-Mutant AAV Vectors Results in Robust Transduction of Neurons in Adult Mice” BioMed Research International, 2013(974819):1-8 (2013).
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2018/066551 (6 pages) (dated Jul. 2, 2020).
[cited by applicant]
Issa et al. “Assessment of Tropism and Effectiveness of New Primate-Derived Hybrid Recombinant AAV Serotypes in the Mouse and Primate Retina” PLoS One, 8(4):e60361 (2013).
[cited by applicant]
Jacobson et al. “Improvement and Decline in Vision with Gene Therapy in Childhood Blindness” The New England Journal of Medicine, 372(20):1920-1926 (2015).
[cited by applicant]
Jang et al. “An Evolved Adeno-associated Viral Variant Enhances Gene Delivery and Gene Targeting in Neural Stem Cells” Molecular Therapy, 19(4):667-675 (2011).
[cited by applicant]
Jefferies et al. “Transferrin receptor on endothelium of brain capillaries” Nature, 312:162-163 (1984) (Abstract only).
[cited by applicant]
Jones et al. “Blood-Brain Barrier Transport of Therapeutics via Receptor-Mediation” Pharmaceutical Research, 24 (9):1759-1771 (2007).
[cited by applicant]
Kadam et al. “Potent Peptidic Fusion Inhibitors of Influenza Virus” Science, 358(6362):496-502 (2017).
[cited by applicant]
Kannan et al. “Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat” The Journal of Clinical Investigation, 85(6):2009-2013 (1990).
[cited by applicant]
Kaplitt et al. “Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial” Lancet, 369(9579):2097-2105 (2007) (Abstract only).
[cited by applicant]
Kay, Mark A. “Selecting the Best AAV Capsid for Human Studies” Molecular Therapy, 23(12):1800-1801 (2015).
[cited by applicant]
Khabou et al. “Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant-7m8” Biotechnology and Bioengineering, 113(12):2712-2724 (2016).
[cited by applicant]
Klimczak et al. “A Novel Adeno-Associated Viral Variant for Efficient and Selective Intravitreal Transduction of Rat Müller Cells” PLoS One, 4(10):e7467 (2009).
[cited by applicant]
Koerber et al. “Molecular Evolution of Adeno-associated Virus for Enhanced Glial Gene Delivery” Molecular Therapy, 17(2):2088-2095 (2009).
[cited by applicant]
Korbelin et al. “Pulmonary Targeting of Adeno-associated Viral Vectors by Next-generation Sequencing-guided Screening of Random Capsid Displayed Peptide Libraries” Molecular Therapy, 24(6):1050-1061 (2016).
[cited by applicant]
Kotchey et al. “A Potential Role of Distinctively Delayed Blood Clearance of Recombinant Adeno-associated Virus Serotype 9 in Robust Cardiac Transduction” Molecular Therapy, 19(6):1079-1089 (2011).
[cited by applicant]
Lawlor et al. “Efficient Gene Delivery and Selective Transduction of Glial Cells in the Mammalian Brain by AAV Serotypes Isolated From Nonhuman Primates” Molecular Therapy, 17(10):1692-1702 (2009).
[cited by applicant]
Lee et al. “Receptor mediated uptake of peptides that bind the human transferrin receptor” European Journal of Biochemistry, 268:2004-2012 (2001).
[cited by applicant]
Li et al. “Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles” Molecular Therapy, 16(7):1252-1260 (2008).
[cited by applicant]
Li et al. “Generation of Novel AAV Variants by Directed Evolution for Improved CFTR Delivery to Human Ciliated Airway Epithelium” Molecular Therapy, 17(12):2067-2077 (2009).
[cited by applicant]
Li et al. “Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune Profiles” Journal of Virology, 86(15):7752-7759 (2012).
[cited by applicant]
Li et al. “Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo” Human Gene Therapy Methods, 26(6):211-220 (2015).
[cited by applicant]
Lisowski et al. “Selection and evaluation of clinically relevant AAV variants in a xenograft liver model” Nature, 506 (7488):382-386 (2014).
[cited by applicant]
Liu et al. “Enhancing gene delivery of adeno-associated viruses by cell-permeable peptides” Molecular Therapy—Methods & Clinical Development, 1(12):1-13 (2014).
[cited by applicant]
Lochrie et al. “Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5” Virology, 353:68-82 (2006).
[cited by applicant]
Maguire et al. “Directed evolution of adeno-associated virus for glioma cell transduction” Journal of Neuro-Oncology, 96(3):337-347 (2010).
[cited by applicant]
Malakoutikhah et al. “Shuttle-mediated drug delivery to the brain” Angewandte Chemie, 50:7998-8014 (2011) (Abstract only).
[cited by applicant]
Manno et al. “Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response” Nature Medicine, 12(3):342-347 (2006).
[cited by applicant]
Marks et al. “Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial” The Lancet Neurol…
[cited by applicant]
Marsic et al. “Vector design Tour de Force: Integrating Combinatorial and Rational Approaches to Derive Novel Adeno-associated Virus Variants” Molecular Therapy, 22(11):1900-1909 (2014).
[cited by applicant]
Matsuzaki et al. “Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain” Neuroscience Letters, 665:182-188 (2018) (Abstract only).
[cited by applicant]
Meairs, Stephen “Facilitation of Drug Transport across the Blood-Brain Barrier with Ultrasound and Microbubbles” Pharmaceutics, 7:275-293 (2015).
[cited by applicant]
Messina et al. “Adeno-Associated Viral Vectors Based on Serotype 3b Use Components of the Fibroblast Growth Factor Receptor Signaling Complex for Efficient Transduction” Human Gene Therapy, 23(10):1031-1042 (2012).
[cited by applicant]
Michelfelder et al. “Peptide Ligands Incorporated into the Threefold Spike Capsid Domain to Re-Direct Gene Transduction of AAV8 and AAV9 In Vivo” PLoS One, 6(8):e23101 (2011).
[cited by applicant]
Michelfelder et al. “Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy” Experimental Hematology, 35(12):1766-1776 (2007) (Abstract only).
[cited by applicant]
Muller et al. “Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors” Nature Biotechnology, 21(9):1040-1046 (2003).
[cited by applicant]
Naso et al. “Adeno-Associated Virus (AAV) as a Vector for Gene Therapy” BioDrugs, 31:317-334 (2017).
[cited by applicant]
Nathwani et al. “Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B” The New England Journal of Medicine, 365:2357-2365 (2011).
[cited by applicant]
Oller-Salvia et al. “Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery” Chemical Society Reviews, 45(17):4690-4707 (2016).
[cited by applicant]
Pei et al. “AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement” Virology, 518:95-102 (2018).
[cited by applicant]
Petrs-Silva et al. “High-efficiency Transduction of the Mouse Retina by Tyrosine-mutant AAV Serotype Vectors” Molecular Therapy, 17(3):463-471 (2009).
[cited by applicant]
Powell et al. “Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism” Gene Therapy, 23(11):807-814 (2016).
[cited by applicant]
Prades et al. “Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor” Biomaterials, 33:7194-7205 (2012).
[cited by applicant]
Pulicherla et al. “Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene Transfer” Molecular Therapy, 19(6):1070-1078 (2011).
[cited by applicant]
Qian et al. “Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway” Pharmacological Reviews, 54:561-587 (2002) (Abstract only).
[cited by applicant]
Qiao et al. “Adeno-Associated Virus Serotype 6 Capsid Tyrosine-to-Phenylalanine Mutations Improve Gene Transfer to Skeletal Muscle” Human Gene Therapy, 21(10):1343-1348 (2010).
[cited by applicant]
Ren et al. “The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2” Biomaterials, 33:3324-3333 (2012) (Abstract only).
[cited by applicant]
Sallach et al. “Tropism-modified AAV Vectors Overcome Barriers to Successful Cutaneous Therapy” Molecular Therapy, 22(5):929-939 (2014).
[cited by applicant]
Salmon et al. “Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera)” Expert Review of Clinical Pharmacology, 7:53-65 (2014).
[cited by applicant]
Schmidt et al. “Cloning and Characterization of a Bovine Adeno-Associated Virus” Journal of Virology, 78 (12):6509-6516 (2004).
[cited by applicant]
Sellner et al. “Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells” Exp Hem…
[cited by applicant]
Sen et al. “Targeted Modifications in Adeno-Associated Virus Serotype 8 Capsid Improves Its Hepatic Gene Transfer Efficiency In Vivo” Human Gene Therapy Methods, 24(2):104-116 (2013).
[cited by applicant]
Shen et al. “Engraftment of a Galactose Receptor Footprint onto Adeno-associated Viral Capsids Improves Transduction Efficiency” Journal of Biological Chemistry, 288(40):28814-28823 (2013).
[cited by applicant]
Tenenbaum et al. “Evaluation of Risks Related to the Use of Adeno-Associated Virus-Based Vectors” Current Gene Therapy, 3(6):545-565 (2003).
[cited by applicant]
Tervo et al. “A designer AAV variant permits efficient retrograde access to projection neurons” Neuron, 92 (2):372-382 (2016).
[cited by applicant]
Varadi et al. “Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors” Gene Therapy, 19(8):800-809 (2012).
[cited by applicant]
Wang et al. “Direct Interaction of Human Serum Proteins with AAV Virions to Enhance AAV Transduction: Immediate Impact on Clinical Applications” Gene Therapy, 24(1):49-59 (2017).
[cited by applicant]
Watakabe et al. “Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex” Neuroscience, 93:144-157 (2015).
[cited by applicant]
Wu et al. “Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism” Journal of Virology, 74(18):8635-8647 (2000).
[cited by applicant]
Yang et al. “A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection” Proceedings of the National Academy of Sciences USA, 106(10):3946-3951 (2009).
[cited by applicant]
Yu et al. “A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery” Gene Therapy, 16(8):953-962 (2009).
[cited by applicant]
Yu et al. “Developing Therapeutic Antibodies for Neurodegenerative Disease” Neurotherapeutics, 10(3):459-472 (2013).
[cited by applicant]
Zhang et al. “Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration” Biomaterials, 176:71-83 (2018).
[cited by applicant]
Zhong et al. “Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses” Proceedings of the National Academy of Sciences USA, 105(22):7827-7832…
[cited by applicant]
Zinn et al. “In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector” Cell Reports, 12:1056-1068 (2015).
[cited by applicant]
“International Search Report and the Written Opinion of the International Searching Authority corresponding to International Patent Application No. PCT/US2018/066551 (9 pages) (mailed Mar. 28, 2019)”.
[cited by applicant]
Chen , et al., ““Molecular Characterization of Adeno-Associated Viruses Infecting Children” Journal of Virology, 79 (23):14781-14792 (2005)”.
[cited by applicant]
Choudhury , et al., ““In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy” Molecular Therapy, 24(7):1247-1257 (2016)”.
[cited by applicant]
Turanli-Yildiz , et al., “, “Protein Engineering Methods and Applications,” Protein Engineering, Chapter 2, pp. 33-58, (2012)”.
[cited by applicant]
Vance, Melisa , et al., “AAV gene therapy for MPS1-associated corneal blindness”, Scientific Reports, 6(1) (Feb. 22, 2016), 2016, 1-10.
[cited by applicant]